Research progress on immunogenicity evaluation of serogroup B meningococcal vaccine.
10.3760/cma.j.cn112150-20210630-00621
- Author:
Fu Yi HAN
1
;
Juan XU
1
;
Li XU
1
;
Zhu Juan SHAO
1
Author Information
1. Institute for Communicable Disease Prevention and Control,Chinese Center for Disease Control and Prevention, Beijing 102206, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Meningitis, Meningococcal/prevention & control*;
Meningococcal Vaccines;
Neisseria meningitidis;
Serogroup;
Vaccines, Combined
- From:
Chinese Journal of Preventive Medicine
2022;56(5):652-658
- CountryChina
- Language:Chinese
-
Abstract:
Epidemic cerebrospinal meningitis (meningococcal meningitis) is an acute respiratory infectious disease with high mortality and serious sequelae. Meningococcal vaccine is an effective measure to prevent and control meningococcal meningitis. At present, group B meningococcal meningitis has become the main prevalent serum group in the world, including China. Meningococcal ACYW and other vaccines are mainly composed of capsular polysaccharides, while the main component of group B meningococcal vaccine is protein, including outer membrane vesicles (OMV) and recombinant protein vaccine. The methods for evaluating the immunogenicity of group B meningococcal vaccine include hSBA and alternative methods such as meningococcal antigen typing system (MATS), flow cytometric meningococcal antigen surface expression assay (MEASURE), genetic meningococcal antigen typing system (gMATS) and bexsero antigen sequence type (BAST). The evaluation of vaccine immunogenicity is the basis of vaccine development and clinical trial research, However, at present, there is no group B meningococcal vaccine in China. Therefore, in this paper, the research progress of immunogenicity evaluation of group B meningococcal vaccine has been reviewed, in order to provide technical guidance for the research and development of group B meningococcal vaccine, immunogenicity evaluation and clinical trial research in China.
